Explains the characteristic tingle/itch felt 10-20 min after a bolus dose of β-alanine — the most user-noticed and most-asked-about side effect of the supplement. β-alanine is a low-affinity but selective agonist of MrgprD (Mas-related G protein-coupled receptor D), a Gq-coupled GPCR expressed on a discrete subpopulation of non-peptidergic C-fiber sensory neurons that innervate skin (Shinohara 2004 identified the receptor; Liu 2012 mapped the itch circuit). Activation drives PLCβ → IP3 → intracellular Ca²⁺ release → depolarization → action potentials in MrgprD⁺ afferents, perceived centrally as paresthesia (tingle, prickle, mild itch) localized to face, scalp, neck, and back — the regions with the densest MrgprD⁺ innervation. The sensation is dose-dependent and saturable; slow-release / split-dose formulations blunt it by keeping plasma β-alanine below the activation threshold (Trexler 2015). Mechanism is histamine-independent — antihistamines don't blunt it — which is why it reads as 'tingle' rather than 'itch' to most users. Downstream channel discrimination: TRPC3 is dispensable (Dong 2017); the conducting current is more likely a calcium-activated chloride channel (TMEM16A/anoctamin-1) and TRPA1-dependent in the longer-tail neuropathic context. Bellinger 2016 shows paresthesia does not impair endurance-cycling performance — useful clinical reassurance.
Organ Systems
nervous
Pathway Steps
beta-alanine → MrgprD activation — via low-affinity but selective agonism of Mas-related GPCR D on non-peptidergic C-fiber sensory neurons (DRG). The harmless tingling from beta-alanine is a specific receptor effect, not general nerve irritation: beta-alanine is an agonist at MrgprD, a Mas-related GPCR expressed selectively on a subset of sensory (C-fiber) neurons that mediate itch and light touch. Identifying MrgprD explained the distinctive, dose-related paresthesia.
MrgprD activation → Gq → PLCβ signaling — via GPCR-Gq coupling; PLCβ hydrolyzes PIP2 → IP3 + DAG. MrgprD couples to Gq, activating phospholipase C-β. This is the standard Gq cascade — the same one used by many itch and irritant receptors — channeling the beta-alanine signal toward calcium release rather than cAMP changes.
Gq → PLCβ signaling → IP3 → ER Ca²⁺ release — via IP3 binds IP3R on ER → cytosolic Ca²⁺ rise; TRPC3 is dispensable as the downstream channel (Dong 2017). PLCβ cleaves PIP2 to IP3, which opens ER IP3 receptors to release stored Ca²⁺ into the cytosol. This rise in intracellular calcium is the second-messenger step that converts receptor activation into electrical excitation of the sensory neuron.
IP3 → ER Ca²⁺ release → C-fiber depolarization (action potential) — via Ca²⁺ activates anoctamin-1 (TMEM16A) Cl⁻ current + voltage-gated Na⁺ — primary afferent fires. The calcium rise (with downstream channel effects) depolarizes the C-fiber to threshold, firing action potentials along these itch/touch-sensing afferents. Because MrgprD-positive fibers are a defined sensory population, the sensation is specific in quality and location rather than diffuse pain.
C-fiber depolarization (action potential) → paresthesia (tingle / prickle / mild itch) — via central perception of MrgprD⁺ afferent firing — face / scalp / neck / back; histamine-independent. The brain interprets this C-fiber input as paresthesia — tingling, prickling, or mild itch, typically on the face, scalp, and hands minutes after a dose. It is benign and self-limiting; splitting the dose or using sustained-release beta-alanine reduces it without affecting the muscle-carnosine benefit.
Known Modulators
beta alanine (substrate) — MrgprD (Gq-coupled GPCR). the perpetrator — bolus doses ≥0.8 g exceed activation threshold and trigger paresthesia in ~70% of users; slow-release or split dosing keeps plasma below threshold while preserving the muscle-carnosine effect
carnosine (substrate) — MrgprD (weaker than free β-alanine). carnosine (β-alanyl-L-histidine) is the storage form; some MrgprD activation but lower potency than free β-alanine — why dietary carnosine from meat does not trigger paresthesia